AIM ImmunoTech advances pancreatic cancer program to pivotal stage
AIM ImmunoTech Inc. has completed dosing in its Phase 2 DURIPANC trial for metastatic pancreatic cancer, combining Ampligen with AstraZeneca's Imfinzi. Primary endpoint analysis is set for December 2026, with topline results due in Q1 2027. The company views the program as a critical value-inflection point supported by positive interim data and orphan drug designation.
*this image is generated using AI for illustrative purposes only.
AIM ImmunoTech Inc. has completed the dosing phase for the final subject in its Phase 2 DURIPANC clinical trial, evaluating Ampligen (rintatolimod) combined with AstraZeneca's Imfinzi (durvalumab) for metastatic pancreatic cancer. This milestone positions the company for a potential pivotal Phase 3 program, with primary endpoint analysis anticipated to begin in December 2026 and topline results expected in Q1 2027. The study is a collaboration involving AIM, AstraZeneca, and Erasmus Medical Center.
The trial's primary endpoint is the Clinical Benefit Rate (CBR), defined as the proportion of patients achieving stable disease, partial response, or complete response at 24 weeks. Secondary endpoint analysis, including Overall Survival (OS) and progression-free survival, is expected to begin in June 2027. This data aims to identify 'super-responder' patient subsets likely to benefit most from Ampligen-based therapy, informing the design of a potential Phase 3 study.
Clinical Foundation and Historical Data
The DURIPANC study builds upon a previous Named Patient Program where Ampligen was used as a monotherapy in late-stage pancreatic cancer. Historical data from that program indicated survival improvements based on specific biomarker stratifications, as shown below:
| Immune Marker Stratification | Progression-Free Survival (Months) | Overall Survival (Months) |
|---|---|---|
| Neutrophil/Lymphocyte Ratio < 4.5 | ||
| Study Data | 17.7 | 34.8 |
| Historical Controls | 8.6 | 12.5 |
| Improvement | 9.1 | 22.3 |
| CA 19-9 < 1000 | ||
| Study Data | 13.1 | 24.1 |
| Historical Controls | 8.6 | 12.5 |
| Improvement | 4.5 | 11.6 |
Strategic Milestones and Outlook
AIM Chief Executive Officer Thomas K. Equels emphasized the company's focus on utilizing exploratory biomarker data to design a Phase 3 study. The company has reported positive interim updates, a favorable safety profile with no significant toxicity, and maintained orphan drug designation for pancreatic cancer in major markets. Additionally, AIM has strengthened its balance sheet and regained compliance with NYSE American continued listing standards.
Management believes the program represents a significant opportunity to create shareholder value, particularly as the biotechnology sector values late-stage oncology assets. With completed enrollment, strengthened intellectual property protection, and ongoing regulatory planning, AIM views the upcoming period as a critical value-inflection point for the Ampligen franchise.
How will the exploratory biomarker data from the DURIPANC trial specifically influence the patient selection criteria for the pivotal Phase 3 study?
What are the potential implications of the topline results for the existing partnership structure between AIM ImmunoTech and AstraZeneca?
Given the favorable safety profile, is AIM considering evaluating Ampligen in combination with other immunotherapies beyond Imfinzi?
17
Access 50+ Readymade Screeners 
Use 200+ Custom Filters 
Get Full Market Insights 
